| Trial ID: | L7109 |
| Source ID: | NCT00732147
|
| Associated Drug: |
Pramlintide Acetate
|
| Title: |
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Pramlintide acetate|DRUG: Placebo
|
| Outcome Measures: |
Primary: Endogenous glucose production, 18 hours | Secondary: Endogenous VLDL-Triglyceride production, 18 hours
|
| Sponsor/Collaborators: |
Sponsor: University of Maryland, Baltimore | Collaborators: Amylin Pharmaceuticals, LLC.
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-04
|
| Completion Date: |
2011-04
|
| Results First Posted: |
|
| Last Update Posted: |
2021-07-22
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00732147
|
